Prelude Capital Management LLC lowered its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 6.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,365 shares of the company’s stock after selling 1,200 shares during the period. Prelude Capital Management […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) insider Aziz Mottiwala sold 2,400 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $20.05, for a total value of $48,120.00. Following the completion of the sale, the insider now directly owns 45,806 […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report)’s share price was up 5.2% during trading on Friday . The company traded as high as $24.52 and last traded at $24.45. Approximately 195,374 shares traded hands during trading, an increase of 30% from the average daily volume of 150,708 shares. The stock had previously closed at […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 1,570,000 shares, a growth of 72.6% from the May 31st total of 909,800 shares. Approximately 8.0% of the shares of the company are sold short. Based on […]
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CFO Leonard M. Greenstein sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, April 20th. The stock was sold at an average price of $14.02, for a total transaction of $70,100.00. Following the transaction, the chief financial officer now owns 26,785 shares in […]